Article :: Atrial fibrillation and bisphosphonate therapy - Journal of Bone and Mineral Research

Home > Current Issue > Article

Perspective

Atrial fibrillation and bisphosphonate therapy

Michael Pazianas^{1 *}, Juliet Compston², Christopher L-H Huang³

¹Institute of Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, United Kingdom
²Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, United Kingdom
³Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, United Kingdom

email: Michael Pazianas (Michael.Pazianas@ndorms.ox.ac.uk)

^*Correspondence to Michael Pazianas, Institute of Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, United Kingdom.

Keywords

bisphosphonates atrial fibrillation calcium magnesium zinc metalloproteinases inflammation statins

Abstract

Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. Recently, concerns have been raised about a possible association between bisphosphonate therapy and atrial fibrillation (AF) following the report of a significant increase in risk of serious AF in women treated with zoledronic acid in the HORIZON study. Subsequent studies have produced conflicting results but have not excluded the possibility of such an association. Currently there is no direct evidence that bisphosphonates exert either acute or chronic effects on cardiac electrophysiology. Nevertheless, altered intracellular electrolyte homeostasis and proinflammatory, profibrotic, and antiangiogenic effects provide potential mechanisms by which atrial conduction could be affected in patients treated with bisphosphonates. In studies in which an increase in risk of AF has been identified, there is no evidence that this translates into increased mortality or increased risk of stroke, and the risk-benefit balance of bisphosphonate therapy in patients with osteoporosis and other forms of metabolic bone disease remains strongly positive. © 2010 American Society for Bone and Mineral Research

Received: 19 July 2009; Revised: 20 November 2009; Accepted: 1 December 2010

Digital Object Identifier (DOI)

10.1359/jbmr.091201 About DOI